stockrowSpruce Biosciences, Inc.
SPRBSpruce Biosciences, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $4.9 million, down 51.3% from fiscal 2023.
- Revenue
- −75.9%
- EPS
- −90.9%
- Free cash flow
- −152.1%
- Total debt
- +427.2%
Quarter to June 2026, against a year earlier
Follow SPRB
Alert me
Spruce Biosciences, Inc. (SPRB) EV/Sales
As of 6 November 2026, Spruce Biosciences, Inc. (SPRB) trades at a EV/Sales of 4.9×. Over the past ten years it has ranged from −6.6× (March 2024) to 18.9× (October 2025); the current reading is higher than 85% of that period. That is below the Biotechnology industry median of 9.0× and above the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2024 | −4.0× | — |
| FY2023 | 2.1× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2024 | −4.0× | — |
| Sep 2024 | −5.4× | — |
| Jun 2024 | −4.7× | — |
| Mar 2024 | −4.4× | — |
| 4 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| CMPX Compass Therapeutics, Inc. compare | n/m |
| TARA Protara Therapeutics, Inc. compare | n/m |
| MENS Jyong Biotech Ltd. compare | n/m |
| PDSB PDS Biotechnology Corporation compare | n/m |
| CUE Cue Biopharma, Inc. compare | 2.7× |
| CHRS Coherus Oncology, Inc. compare | 4.4× |
| SPRB Spruce Biosciences, Inc. | 4.9× |
| MOLN Molecular Partners AG Sponsored ADR compare | 9.3× |
| YARW Yarrow Bioscience, Inc compare | 118× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)